388 related articles for article (PubMed ID: 16518960)
1. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
[TBL] [Abstract][Full Text] [Related]
2. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
4. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
[TBL] [Abstract][Full Text] [Related]
5. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
6. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
7. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
[TBL] [Abstract][Full Text] [Related]
8. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
9. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
10. Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.
Rathbun CR; Liedtke MD; Blevins SM; Harrison D; Lockhart SM; Salvaggio M; Acosta EP
HIV Clin Trials; 2009; 10(5):328-36. PubMed ID: 19906626
[TBL] [Abstract][Full Text] [Related]
11. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
[TBL] [Abstract][Full Text] [Related]
12. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
[TBL] [Abstract][Full Text] [Related]
13. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
Huang F; Scholl P; Huang DB; MacGregor TR; Vinisko R; Castles MA; Berger F; Robinson P
J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Malan N; Su J; Mancini M; Yang R; Wirtz V; Absalon J; McGrath D;
AIDS Care; 2010 Jun; 22(6):677-86. PubMed ID: 20467943
[TBL] [Abstract][Full Text] [Related]
15. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
[TBL] [Abstract][Full Text] [Related]
16. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Burger DM; Agarwala S; Child M; Been-Tiktak A; Wang Y; Bertz R
Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
19. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Keiser PH; Nassar N
Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
[TBL] [Abstract][Full Text] [Related]
20. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
